Io Biotech, Inc.2024财年第二财季实现净利润-20.69百万美元，同比增加2.31%

自选股智能写手08-18

8月18日，Io Biotech, Inc.（IOBT.US）公布财报，公告显示公司2024财年第二财季净利润为-20.69百万美元，同比增加2.31%；其中营业收入为0.00美元，每股基本收益为-0.31美元。从资产负债表来看，Io Biotech, Inc.（IOBT.US）总负债15.20百万美元，其中短期债务678000.00美元，资产负债比为0.08，流动比率为0.08。机构评级：截至...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2460736929?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-18 00:04","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2460736929","market":"us","top_or_hot":-1,"title":"Io Biotech, Inc.2024财年第二财季实现净利润-20.69百万美元，同比增加2.31%","media":"自选股智能写手","content":"<div>\n<p>8月18日，Io Biotech, Inc.（IOBT.US）公布财报，公告显示公司2024财年第二财季净利润为-20.69百万美元，同比增加2.31%；其中营业收入为0.00美元，每股基本收益为-0.31美元。从资产负债表来看，Io Biotech, Inc.（IOBT.US）总负债15.20百万美元，其中短期债务678000.00美元，资产负债比为0.08，流动比率为0.08。机构评级：截至...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081800065295a167fb&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Io Biotech, Inc.2024财年第二财季实现净利润-20.69百万美元，同比增加2.31%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIo Biotech, Inc.2024财年第二财季实现净利润-20.69百万美元，同比增加2.31%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-18 00:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081800065295a167fb&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月18日，Io Biotech, Inc.（IOBT.US）公布财报，公告显示公司2024财年第二财季净利润为-20.69百万美元，同比增加2.31%；其中营业收入为0.00美元，每股基本收益为-0.31美元。从资产负债表来看，Io Biotech, Inc.（IOBT.US）总负债15.20百万美元，其中短期债务678000.00美元，资产负债比为0.08，流动比率为0.08。机构评级：截至...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081800065295a167fb&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IOBT","symbol_name":"IO Biotech, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081800065295a167fb&s=b","article_id":"2460736929","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081800065295a167fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2460736929","pubTimestamp":1723910665,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"8月18日，Io Biotech, Inc.公布财报，公告显示公司2024财年第二财季净利润为-20.69百万美元，同比增加2.31%；其中营业收入为0.00美元，每股基本收益为-0.31美元。从资产负债表来看，Io Biotech, Inc.总负债15.20百万美元，其中短期债务678000.00美元，资产负债比为0.08，流动比率为0.08。机构评级：截至2024年8月18日，当前有5家机构对Io Biotech, Inc.目标价做出预测，其中目标均价为8.80美元，其中最低目标价为5.00美元，最高目标价为12.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"IOBT":"IO Biotech, Inc."},"translate_title":"Io Biotech, Inc. achieved net profit of-US $20.69 million in the second fiscal quarter of fiscal year 2024, a year-on-year increase of 2.31%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOBT":0.9},"content_text":"8月18日，Io Biotech, Inc.（IOBT.US）公布财报，公告显示公司2024财年第二财季净利润为-20.69百万美元，同比增加2.31%；其中营业收入为0.00美元，每股基本收益为-0.31美元。从资产负债表来看，Io Biotech, Inc.（IOBT.US）总负债15.20百万美元，其中短期债务678000.00美元，资产负债比为0.08，流动比率为0.08。机构评级：截至2024年8月18日，当前有5家机构对Io Biotech, Inc.目标价做出预测，其中目标均价为8.80美元，其中最低目标价为5.00美元，最高目标价为12.00美元。公司简介：IO Biotech Inc 是一家临床阶段的生物制药公司，开发基于 T-win 技术平台的新型免疫调节癌症疫苗。 候选产品旨在诱导免疫系统同时靶向和破坏调节肿瘤诱导的免疫抑制的多种途径。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2460736929"}